The TL1A inhibitor tulisokibart was associated with better clinical, endoscopic, and patient-reported outcomes than placebo in patients with moderately to severely active UC in the induction part of the phase 2 ARTEMIS-UC trial (NCT04996797) [1]. During the 12-week induction phase, participants in the tulisokibart arm (n=68) received 1,000 mg intravenously administered tulisokibart at day 1, followed by 500 mg tulisokibart, every 4 weeks. Responders could enter the open-label extension part to receive tulisokibart maintenance therapy for up to 170 weeks. The responders (n=47) were randomised 1:1 to 250 mg tulisokibart, every 4 weeks, or to 100 mg tulisokibart, every 4 weeks. Dr Christopher Ma (University of Calgary, Canada) presented the findings after 50 weeks of follow-up [2].
The clinical remission rate was 32% in the 100 mg arm and 48% in the 250 mg arm. Next, endoscopic improvement was observed in 36% and 48% of the participants in the 100 mg arm and 250 mg arm, respectively. Furthermore, the clinical response rates were 59% and 68% for the low-dose and high-dose arms. Histologic improvement was documented for 67% of the participants in the 100 mg arm and 70% of the participants in the 250 mg arm.
âThe severe adverse event rates were low, with 10% [n=3] of the patients in the 100 mg arm and 3% [n=1] of the patients in the 250 mg arm,â expressed Dr Ma. No acute infusion reactions or peri-infusion reactions were seen. The infection rate was 37% in the 100 mg arm and 46% in the 250 mg arm. âThese were, however, predominantly upper respiratory infections. We did not see any serious infections or infections that would be related to systemic immunosuppression, such as herpes zoster,â clarified Dr Ma.
Altogether, tulisokibart displayed encouraging long-term efficacy data and favourable safety results in the current phase 2 study, supporting further investigations of this agent in phase 3 studies.
- Sands BE, et al. J Crohns Colitis. 2023;17:i56-i59 (Abstract OP40)
- Ma C, et al. Long-term efficacy and safety of tulisokibart in patients with ulcerative colitis: results from the open-label extension period of the phase 2 ARTEMIS-UC study. OP194, UEG Week 2024, 12â15 October, Vienna, Austria.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« An accelerated treatment approach may save lives in pancreatic walled-off necrosis Next Article
Treatment of residual RCC following first-line systemic therapy »
« An accelerated treatment approach may save lives in pancreatic walled-off necrosis Next Article
Treatment of residual RCC following first-line systemic therapy »
Table of Contents: UEGW 2024
Featured articles
Tamuzimod delivers promising long-term data in ulcerative colitis
CULTIVATE: Good signal for etrasimod in Crohnâs disease
Online First
Upadacitinib associated with normalisation of HRQoL in UC
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
New insights into perianal fistulising CD pathogenesis may lead to new therapeutics
TL1A inhibitor tulisokibart shows potential in ulcerative colitis
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Encouraging results for L-carnitine in non-alcoholic fatty liver disease
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Tamuzimod delivers promising long-term data in ulcerative colitis
Cendakimab meets primary endpoints in eosinophilic oesophagitis
How useful is colonoscopy for constipation in young women?
Guar gum alleviates IBS-related constipation in randomised-controlled trial
CULTIVATE: Good signal for etrasimod in Crohnâs disease
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Is FMT a viable option to treat primary C. difficile infections?
Extending ustekinumab dosing interval does not influence drug survival in IBD
TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
Related Articles
August 31, 2021
Worse renal function after radical versus partial nephrectomy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com